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Severe sepsis is a major healthcare problem and the
early initiation of antimicrobials is one of the few
measures associated with improved outcomes.
However, antibiotic overuse is an increasing problem
in critical care. Of several potential biomarkers for
antibiotic stewardship, procalcitonin represents the
most widely studied and validated. In this commentary
we address the current literature on the use of
biomarkers to guide antimicrobial therapy in the
critically ill and discuss its limitations and future
directions.geneity of studied patients, specifically the wide variation ofIn a previous issue of Critical Care, Prkno and colleagues
report a meta-analysis of the current literature evaluating
the role of procalcitonin (PCT) to guide the duration of
antimicrobial therapy in patients with severe sepsis and
septic shock admitted to the ICU [1]. In these patients early
initiation of antimicrobials is one of the few measures asso-
ciated with improved outcomes in this high mortality sce-
nario [2]. However, overuse of antimicrobials - related
either to missed opportunities to reduce the spectrum of
activity or to unnecessarily long treatment regimens - has
become an increasing problem in the past decades. Besides
being associated with worse outcomes, antimicrobial resist-
ance is becoming even more worrisome.
Clinical judgment remains the most valuable tool when
decisions regarding the use of antibiotics are taken, but
with important shortcomings. While features of disease
severity at presentation may be quite nonspecific, the* Correspondence: jorgesalluh@gmail.com
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2014characteristics of clinical response to therapy are usually
inaccurate and occur late in the course of disease. In such
a scenario, biomarkers have been proposed as important
tools to aid the decision-making process. Of several po-
tential candidates, PCT represents the most widely stud-
ied and validated.
What becomes clearer from current studies in
sepsis
Several systematic reviews have addressed the issue of
PCT-guided therapy. Prkno and colleagues [1] focused on
critically ill patients with severe sepsis or septic shock. By
doing so, they cleverly avoided biases related to the hetero-
severity that may exist between infected individuals (for ex-
ample, from mild to severe community-acquired pneumo-
nia) [3]. Using these inclusion criteria, seven randomized
clinical trials were enrolled, totaling 1,075 patients. As their
main conclusions, Prkno and colleagues provide a clear
message for ICU physicians: we can safely reduce the dur-
ation of antimicrobial therapy in patients with severe sepsis
or septic shock using PCT-guided protocols (hazard ratio
1.27, 95% confidence interval 1.01 to 1.53). Nevertheless,
the authors acknowledge the many limitations of their
study (for example, heterogeneity of PCT protocols) and
emphasize that further information on major outcomes,
such as length of stay and mortality, is required from future
studies.
Limitations of current studies and their clinical
implications
Despite their important contribution, most trials evaluat-
ing PCT-guided antibiotic therapy present several limita-
tions that preclude their safe extrapolation to the clinical
decision-making process [3]. Namely, the high rate of
patient exclusion (reaching >80% in the Svoboda and
colleagues trial [4]) and the high rate of algorithmtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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disregard the impact of renal failure as well as renal re-
placement therapy on PCT levels, and above all the het-
erogeneity of duration of antibiotic therapy in the
controls. Contrary to Prkno and colleagues’ opinion,
since 2003 [6,7] it has been clear that the duration of
antibiotic therapy could be safely reduced in critically ill








- PCT decrease 90% 
- CRP decrease 50% 
or
After 7 full days of antibiotics
Consider stopping antibiotics





Assessment after 5 full days of antibiotics
- No signs of active infection, SOFA 
decreasing
and
- PCT decrease 90% and/or CRP decrease
50%  
- Obtain cultures
- Initiate antibiotic therapy if




and until culture results
are available
- Consider using PCT or
CRP to guide decision to











Figure 1 Use of C-reactive protein and procalcitonin to guide antimic
tested only in a single center trial with predominantly medical ICU patients
example, febrile neutropenia) or to patients with infections requiring long-
abscess, bacteremia due to Staphylococcus aureus). £Most trials investigating
guiding the decision of antibiotic interruption. Initiating antibiotics for all c
sion, regardless the levels of laboratory biomarkers. However, this decision
to diagnose infection, and different cutoff levels have been proposed in th
no proven infection (for example, negative cultures) regardless the levels otherapy should be used as the best care in clinical trials.
Besides, some infections (for example, infectious endo-
carditis, and nosocomial infections due to Pseudomonas
aeruginosa or Acinetobacter baumannii) were not sys-
tematically evaluated. Finally, the costs associated with
daily measurement of PCT in all ICU patients should
not be ignored, since we have cheaper and widely avail-
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robial therapy in critically ill patients. C-reactive protein (CRP) was
. This flowchart does not apply to immune-compromised patients (for
term antibiotic therapy (for example, infectious endocarditis, cerebral
procalcitonin (PCT)-guided protocols tested the role of this marker in
ritically ill patients with suspected infection is probably the safest deci-
must be reassessed daily. PCT and CRP are proposed as additional tools
e literature. ¶Consider stopping antibiotics before day 7 in patients with
f CRP or PCT. SOFA, Sequential Organ Failure Assessment.
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current clinical use of biomarkers in sepsis
With the previously mentioned shortcomings in mind, it
is legitimate to ask how can we properly use biomarkers
such as PCT and C-reactive protein (CRP) to guide anti-
microbial therapy (initiation and duration) in severe sep-
sis. First, we believe that future clinical trials should use
less strict entry criteria that would better reflect our
real-life ICU patients with sepsis. Second, a great deal of
effort must be made to conduct multicenter studies in-
volving large numbers of patients, ideally in different re-
gions of the world. Lastly, biomarker-guided strategies
must be tested against a comparator that actually reflects
the 'best care' (that is, implementation of the best avail-
able evidence), and not the highly variable 'standard
care'. In our opinion, it means comparing PCT algo-
rithms with control treatment in which the maximum
durations of antibiotic therapy is setup in 7 days, or even
in 5 days (for example, severe sepsis without shock)
[6,7,9]. Until these studies are performed and their re-
sults become available, clinicians should perhaps use a
'double-trigger' strategy as proposed by Oliveira and col-
leagues [8]. In all patients, antibiotics were stopped ac-
cording to the clinical course and either decreases in
biomarker levels, according to an algorithm, or the com-
pletion of 7 days of treatment, whichever came first. In
this single-center study evaluating patients with severe
sepsis and septic shock, PCT or CRP were similarly effect-
ive to ensure early interruption of antibiotics (day 4/5).
To achieve safe and efficient short-course antimicro-
bial therapy in severe sepsis we propose an algorithm
that may aid clinicians in their decision-making process
(Figure 1). Using such a protocol, which remains to be
validated in multicenter studies, we would be applying
two very sound and validated concepts: patients with a
fast response pattern to antibiotic therapy (early and
substantial decrease in biomarker levels) have better out-
comes [10-12]; and most cases of severe infections may
be treated with 7 days of antibiotic therapy [6,7,9].
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